Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
579 DKK | +1.40% | -2.69% | +24.84% |
Apr. 22 | U.S. Futures, European Stocks Rise | DJ |
Apr. 16 | GRI Bio Receives South Korea Patent for Liver Inflammatory Condition Treatments | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- The firm trades with high earnings multiples: 24.37 times its 2024 earnings per share.
- The company is not the most generous with respect to shareholders' compensation.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Electrical Components & Equipment
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+24.84% | 4.45B | B | ||
+4.53% | 149B | A | ||
+34.66% | 130B | B+ | ||
+19.57% | 130B | B+ | ||
+12.90% | 62.82B | A- | ||
+7.65% | 41.04B | B | ||
+94.65% | 35B | C | ||
-9.78% | 32.1B | B | ||
+6.26% | 32.1B | B | ||
+3.97% | 27.31B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NKT Stock
- Ratings NKT A/S